October 15, 2019
LONDON—Covington has advised BenevolentAI on its $90 million investment from Temasek, a Singapore-headquartered investment company.
BenevolentAI aims to improve the lives of patients suffering from diseases with no effective treatment. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy, and lower the development time and costs of new treatments.
The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development. BenevolentAI will continue to advance its growing pipeline of internal drug development programmes and collaborations with strategic partners across its key therapeutic areas.
The Covington team was led by Simon Amies (corporate) and included Camilla Rogers (corporate), Denitsa Marinova (corporate) and Guy Dingley (tax and incentives).